View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAltitude Acquisition 将来の成長Future 基準チェック /06現在、 Altitude Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長12.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.お知らせ • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .お知らせ • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".お知らせ • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.お知らせ • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.お知らせ • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.お知らせ • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Altitude Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:ALTU - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2023N/A-4-1-1N/A6/30/2023N/A-2-1-1N/A3/31/2023N/A-1-1-1N/A12/31/2022N/A900N/A9/30/2022N/A1300N/A6/30/2022N/A1100N/A3/31/2022N/A3000N/A12/31/2021N/A15-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: ALTUの予測収益成長が 貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ALTUの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ALTUの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ALTUの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ALTUの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALTUの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/03/13 04:56終値2024/03/13 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Altitude Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.
お知らせ • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .
お知らせ • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".
お知らせ • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.
お知らせ • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
お知らせ • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.
お知らせ • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment.